2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2018
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching
Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.Peer-Reviewed Original ResearchConceptsUnresectable hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaMacrovascular invasionPropensity matchingOverall survivalEnd-stage liver disease (MELD) scoreBarcelona Clinic Liver Cancer stageVeterans Health Administration hospitalsInitiation of sorafenibSignificant hepatic dysfunctionLiver Disease scoreRetrospective cohort studyAdjuvant transarterial chemoembolizationLiver Cancer stageMulti-institutional studySorafenib initiationHepatic dysfunctionCohort studyMost patientsSystemic therapyPrimary outcomeUnadjusted analysesMultimodal therapySubgroup analysis